CA 27-29 in patients with breast cancer with pulmonary fibrosis

A series of 4 patients with breast cancer who have persistent elevation in CA 27.29 are reported, finding that false-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Cancer antigen (CA) 27-29, which is expressed on most carcinoma cells, is a soluble form of glycoprotein MUC1. It is overexpressed in tumors involving glandular epithelial cells, such as breast tumors. Measurement of CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. Although serial determination of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. False-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Herein, we report a series of 4 patients with breast cancer (2 patients with interstitial lung fibrosis and 2 patients with nonspecific fibrotic lung changes) who have persistent elevation in CA 27.29 (normal, <38 U/mL).

Cancers, Free Full-Text

Frontiers Therapeutically Targeting Cancers That Overexpress FOXC1: A Transcriptional Driver of Cell Plasticity, Partial EMT, and Cancer Metastasis

Dr. Sobha Kurian, MD – Morgantown, WV

Dr. Mudussara A. Khan, MD, Daytona Beach, FL, Oncologist

PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

Genes & Cancer A tumor specific antibody to aid breast cancer screening in women with dense breast tissue

CA 27-29 in patients with breast cancer with pulmonary fibrosis.

Table 4 from Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.

Recent Progress in Detection of Breast Cancer Biomarkers by Clinical and Imprinting Polymer-Based Sensors

Tumor Markers for Breast Cancer: Benefits, Drawbacks, Results & More

PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis

Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing

Cancers, Free Full-Text